CAMBRIDGE, Mass., July 29, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:
|
What: |
Vericel Corporation Second-Quarter 2015 Earnings Call |
|
When: |
Wednesday, August 12, 2015 at 8:00am (ET) |
|
Where: |
http://investors.vcel.com/events.cfm |
|
How: |
The conference call will be available live in the Investors section of the Vericel |
|
|
website at http://investors.vcel.com/events.cfm. Please access the site at least 15 |
|
|
minutes prior to the scheduled start time in order to download the required audio |
|
|
software if necessary. |
|
|
|
|
|
To participate in the live call by telephone, please call (877) 312-5881 and |
|
|
reference Vericel Corporation second-quarter 2015 investor conference call. If |
|
|
calling from outside the U.S., please use the international phone number (253) |
|
|
237-1173. |
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until Friday, August 12, 2016. A replay of the call will also be available until 11:59 pm (EDT) on Sunday, August 16, 2015 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 83124058.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
